Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection

Respir Care. 2022 May;67(5):629-630. doi: 10.4187/respcare.10067.

Authors

Akhilesh Mahajan¹, Jonathan Moore¹, Anup K Singh², Margarita Oks¹

Affiliations

¹ Department of Pulmonary and Critical Care Medicine mLenox Hill HospitalNorthwell Health SystemNew York, New York.
² Department of Pulmonary and Critical Care Medicine mLenox Hill HospitalNorthwell Health SystemNew York, New York asingh21@northwell.edu.

PMID: 35473844
DOI: 10.4187/respcare.10067

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 Drug Treatment*
Humans
SARS-CoV-2

Substances

Antibodies, Monoclonal, Humanized
tocilizumab